Cytokine aqueous concentrations after cataract surgery and corresponding 1 month retinopathy and maculopathy for each study eye
| Baseline | Day 1 | 1 Week | 1 Month | 1 Month clinical status | |
|---|---|---|---|---|---|
| Macular hyperfluorescence on fundus fluorescein angiography, No change compared to baseline, CSMO, clinically significant macular oedema. VEGF, HGF, and IL-1β in pg/ml, PEDF in μg/ml. NA, no information available. At baseline there was no macular hyperfluorescence or CSMO; QPDR, quiescent proliferative retinopathy; Low risk PDR, low risk proliferative retinopathy; Severe NPDR, severe non-proliferative retinopathy. | |||||
| Eye 1 | QPDR | QPDR | |||
| VEGF | 83.6 | 2071.5 | 113 | 465.4 | Hyperfluorescence |
| HGF | 101 | 665 | 1105 | 227 | |
| IL-1β | 2.6 | 22.6 | 3.7 | 2.8 | |
| PEDF | 0.97 | 0.77 | 0.6 | 0.65 | |
| Eye 2 | Low risk PDR | Low risk PDR | |||
| VEGF | 53 | 1920 | 41 | 179 | Hyperfluorescence |
| HGF | 119 | 953 | 1105 | 1214 | |
| IL-1β | 0.65 | 8.02 | 10.9 | 2.0 | |
| PEDF | 0.72 | 1.53 | 0.57 | 0.55 | |
| Eye 3 | Severe NPDR | No change | |||
| VEGF | 22.4 | 380 | NA | NA | No change |
| HGF | 131 | 620 | NA | NA | |
| IL-1β | 1.26 | 2.2 | NA | NA | |
| PEDF | 1.73 | 1.21 | NA | NA | |
| Eye 4 | QPDR | QPDR | |||
| VEGF | 44.5 | 722.7 | NA | NA | Hyperfluorescence |
| HGF | 81 | 529.5 | NA | NA | |
| IL-1β | 5.18 | 18.6 | NA | NA | |
| PEDF | 0.50 | 1.7 | |||
| Eye 5 | Severe NPDR | Severe NPDR | |||
| VEGF | 86.6 | 336 | 2.6 | 65.8 | CSMO |
| HGF | 131 | 2042.7 | NA | 2975 | |
| IL-1β | 2.32 | 31.7 | NA | NA | |
| PEDF | 0.82 | 3.18 | 2.63 | 0.71 | |
| Eye 6 | Low risk PDR | Low risk PDR | |||
| VEGF | NA | 1418 | 203 | 811 | No change |
| HGF | NA | NA | NA | NA | |
| IL-1β | NA | NA | NA | NA | |
| PEDF | NA | NA | NA | NA | |
| Eye 7 | QPDR | QPDR | |||
| VEGF | 114 | 517 | 192 | 119 | No change |
| HGF | NA | NA | NA | NA | |
| IL-1β | NA | NA | NA | NA | |
| PEDF | NA | NA | NA | NA | |